Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGP-101
- Development stage
- Preclinical
- Lead developer
- Deargen
01
Overview
DGP-101 is a **preclinical immuno-oncology drug discovery program** from Deargen. Publicly available pipeline information identifies it as a Deargen-developed candidate in the 4D Program and places it at the **Hit Discovery** stage for **immuno-oncology**, but does **not disclose a molecular target, modality, route, formulation, or detailed mechanism of action**. Based on the available source material, DGP-101 should currently be treated as an early-stage proprietary oncology asset rather than a clinically characterized therapeutic product.
- Other names
- DGP-101-Deargen-Immuno-oncologyDGP101-Deargen-Immuno-oncologyDGP 101-Deargen-Immuno-oncology
Beyond the preview
Go deeper on DGP-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGP-101.